Literature DB >> 16039577

The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance.

Christopher A Lazarski1, Francisco A Chaves, Scott A Jenks, Shenhong Wu, Katherine A Richards, J M Weaver, Andrea J Sant.   

Abstract

T cell priming to exogenous antigens reflects regulated antigen processing in dendritic cells, subsequent homing to lymph nodes, sustained interactions between T cells and antigen-bearing dendritic cells, and, ultimately, selective T cell activation and differentiation. In this study, we test the hypothesis that an intrinsic property of the class II:peptide complex is a key determinant that dictates the specificity of an emerging CD4 T cell response. We found that immunodominant peptides possess extremely long half-lives with class II molecules (t(1/2) > 150 hr), whereas cryptic peptides displayed half-lives of less than 10 hr. Furthermore, and most importantly, by using a peptide shuttle vector and four independent antigens, we demonstrate a direct, causative relationship between the half-life of peptide epitopes and their immunogenicity in vivo. Taken collectively, our results suggest the half-life of class II:peptide complexes is the primary parameter that dictates the ultimate hierarchy of the elicited T cell response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039577     DOI: 10.1016/j.immuni.2005.05.009

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  105 in total

1.  The memory phase of the CD4 T-cell response to influenza virus infection maintains its diverse antigen specificity.

Authors:  Katherine A Richards; Francisco A Chaves; Andrea J Sant
Journal:  Immunology       Date:  2011-03-29       Impact factor: 7.397

2.  Pharmacogenetics and the immunogenicity of protein therapeutics.

Authors:  Chen Yanover; Nisha Jain; Glenn Pierce; Tom E Howard; Zuben E Sauna
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

3.  Loss in CD4 T-cell responses to multiple epitopes in influenza due to expression of one additional MHC class II molecule in the host.

Authors:  Jennifer L Nayak; Andrea J Sant
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

Review 4.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

Review 5.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

6.  A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.

Authors:  Liusong Yin; Lawrence J Stern
Journal:  J Immunol Methods       Date:  2014-02-25       Impact factor: 2.303

7.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

8.  Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Authors:  Mikyung Kim; Likai Song; James Moon; Zhen-Yu J Sun; Anna Bershteyn; Melissa Hanson; Derek Cain; Selasie Goka; Garnett Kelsoe; Gerhard Wagner; Darrell Irvine; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

9.  Peptide-MHC class II complex stability governs CD4 T cell clonal selection.

Authors:  Christina K Baumgartner; Andrea Ferrante; Mika Nagaoka; Jack Gorski; Laurent P Malherbe
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

10.  Vaccine adjuvants alter TCR-based selection thresholds.

Authors:  Laurent Malherbe; Linda Mark; Nicolas Fazilleau; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Immunity       Date:  2008-05-01       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.